Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
9°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cybin Inc
(NY:
CYBN
)
10.64
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cybin Inc
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
38
39
Next >
Major Psychedelic Drug Stocks Went Up 7% This Week; Still Down 46% YTD
December 03, 2022
The 6 major psychedelic stocks researching the treatment of a variety of mental illnesses were UP 7% this week and are UP 3 % in the last 6 weeks. The 6 therapy clinic stocks went UP 3% this week and...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From December 2, 2022
December 02, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
December 02, 2022
On Friday, 72 companies hit new 52-week lows.
Via
Benzinga
Psychedelic Stock Gainers And Losers From December 1, 2022
December 01, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 30, 2022
November 30, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
November 30, 2022
During Wednesday's session, 107 stocks hit new 52-week lows.
Via
Benzinga
Revive Therapeutics, Seelos Therapeutics Among Top Psychedelic Movers Of Today
November 29, 2022
Via
Benzinga
Revive Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
November 28, 2022
Via
Benzinga
Cannabis Category Performances Last Week Ranged From +5.2% To -2.3%
November 27, 2022
The 5 categories in the cannabis sector perform quite differently week to week and last week was no exception. This article is a summary of how each category performed last week, in descending order...
Via
Talk Markets
Psychedelic Stock Gainers And Losers From November 25, 2022
November 25, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 24, 2022
November 24, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 23, 2022
November 23, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 22, 2022
November 22, 2022
Via
Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
November 21, 2022
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 21, 2022
November 21, 2022
Via
Benzinga
Psychedelic Drug Stocks Index Continued To Decline Last Week
November 20, 2022
This article highlights the performances of the 6 constituents in the munKNEE Psychedelic Drug Stocks Index last week and in the last 3 weeks and the extent to which each company is likely to encounter...
Via
Talk Markets
Biomind Labs, ATAI Life Sciences Among Top Psychedelic Movers Of Today
November 18, 2022
Via
Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
November 17, 2022
Via
Benzinga
Psychedelic Stock Gainers And Losers From November 16, 2022
November 16, 2022
Via
Benzinga
GH Research, Seelos Therapeutics Among Top Psychedelic Movers Of Today
November 15, 2022
Via
Benzinga
Cybin Shares Q2 Financial & Business Results, Focus On Licensing Deals For Preclinical Assets
November 15, 2022
Cybin Inc. (NYSE: CYBN) reported its unaudited financial results for its second quarter ended September 30, 2022, and provided business highlights for the period.
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Recent Business Highlights, Presentation of CYB003 Preclinical Data at Neuroscience 2022
November 15, 2022
Via
Investor Brand Network
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
November 15, 2022
From
Cybin Inc.
Via
Business Wire
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
November 14, 2022
From
Cybin Inc.
Via
Business Wire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
November 14, 2022
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Retirement
Exposures
Pension
Product Safety
Clinical Stage Psychedelic Stock Index Up 6%; Therapy Clinic Stocks Down 8%
November 14, 2022
We highlight the performance of our Psychedelic Drug Stocks Index and the 6 psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of different psychedelic...
Via
Talk Markets
A Comparison Of 5 Psychedelic ETFs And Indices
November 11, 2022
A look at 2 psychedelic ETFs and 3 tracking (non-trading) indices in the sector.
Via
Talk Markets
Compass Pathways, Mind Medicine Among Top Psychedelic Movers Of Today
November 10, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 12.17% at $10.05
Via
Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Progress on Clinical Path for CYB004
November 10, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
November 10, 2022
From
Cybin Inc.
Via
Business Wire
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
